Africa: Acoziborole Winthrop, Developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as Three-tablet, Single-Dose Treatment For Most Common Form of Sleeping Sickness
Kinshasa / Paris / Geneva / Amsterdam — • Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness • The therapy, given as a single dose of three tablets, could offer a simpler…
